FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Follistatin-344

FS-344 / Follistatin

Growth Factors

Follistatin-344 is a recombinant protein corresponding to the full-length FS344 isoform of human follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and other TGF-beta superfamily members including activins. By inhibiting myostatin, it removes the primary negative regulator of skeletal muscle growth, potentially allowing significant muscle hypertrophy. It is a research compound investigated in gene therapy and recombinant protein contexts for muscular dystrophy, age-related sarcopenia, and muscle wasting conditions.

作用機序

Activin-binding protein that potently inhibits myostatin, a negative regulator of muscle growth. Blocking myostatin removes the genetic brake on muscle hypertrophy. Also inhibits FSH (follicle-stimulating hormone) as activin is required for FSH release.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 100-200mcg daily via subcutaneous injection for 10-30 days. Short cycles due to potential FSH suppression. Some protocols use 50mcg daily for extended periods.

研究ノート

Clinical Research Status

Follistatin-344 gene therapy (AAV-delivered) has been evaluated in Phase 1/2 clinical trials for inclusion body myositis and Becker muscular dystrophy at Nationwide Children's Hospital. Recombinant protein administration remains purely experimental with no formal clinical trials for the injectable form. The gene therapy approach (delivering the follistatin gene via adeno-associated virus) has shown more clinical progress than exogenous protein administration due to delivery challenges.

Key Published Findings

Animal studies demonstrate that follistatin overexpression produces dramatic muscle hypertrophy (up to 100% increase in muscle mass in mice) by antagonizing myostatin and activin A signaling. Gene therapy trials in humans showed modest improvements in muscle function and walking distance in inclusion body myositis patients. Recombinant follistatin protein has limited bioavailability due to rapid clearance, proteolytic degradation, and challenges in achieving sustained tissue-level concentrations sufficient for myostatin neutralization.

Safety Profile

Gene therapy approaches carry standard AAV-associated risks including immune responses to the viral vector and potential insertional mutagenesis. For recombinant protein, theoretical concerns include effects on reproductive function (activins regulate FSH secretion) and potential tumor promotion through TGF-beta pathway inhibition. No systematic human safety data exists for subcutaneous or intramuscular injection of recombinant follistatin-344 protein outside of gene therapy trials.

Comparison to Related Compounds

Unlike ACE-031 (a soluble activin receptor decoy) which was discontinued due to safety concerns, follistatin is an endogenous protein with a natural role in myostatin regulation. Compared to direct myostatin antibodies (stamulumab/MYO-029), follistatin has broader activity by also neutralizing activins and other TGF-beta ligands. The FS344 isoform is processed into FS315 and FS303 forms with different tissue distributions and binding protein interactions.

Community Observations

The research community notes significant skepticism about the efficacy of subcutaneously injected recombinant follistatin-344 reaching muscle tissue at concentrations sufficient to meaningfully inhibit myostatin. Most experts consider the gene therapy approach far more promising than protein injection for achieving sustained myostatin inhibition. Quality control of commercially available recombinant follistatin is a major concern, as proper protein folding is critical for bioactivity.

半減期

~Unknown (protein)

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Store at -20C for long term. Refrigerate 2-8C for short term.

再溶解

Refrigerate 2-8C. Use within 7 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

FS-344Follistatin

よくある質問

Follistatin-344とは何ですか?

Follistatin-344 is a recombinant protein corresponding to the full-length FS344 isoform of human follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and other TGF-beta superfamily members including activins. By inhibiting myostatin, it removes the primary negative regulator of skeletal muscle growth, potentially allowing significant muscle hypertrophy. It is a research compound investigated in gene therapy and recombinant protein contexts for muscular dystrophy, age-related sarcopenia, and muscle wasting conditions.

Follistatin-344はどのように作用しますか?

Activin-binding protein that potently inhibits myostatin, a negative regulator of muscle growth. Blocking myostatin removes the genetic brake on muscle hypertrophy. Also inhibits FSH (follicle-stimulating hormone) as activin is required for FSH release.

Follistatin-344の米国での規制状況は?

Research chemical (not FDA-approved)

Follistatin-344の半減期は?

~Unknown (protein)

Follistatin-344の別名は?

FS-344, Follistatin

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む